NASDAQ:TTOO - T2 Biosystems Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding T2 Biosystems Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.15 -0.01 (-0.86 %) (As of 12/13/2019 04:00 PM ET) Add Compare Today's Range$1.13Now: $1.15▼$1.1850-Day Range$1.15MA: $1.87▼$2.9952-Week Range$0.52Now: $1.15▼$5.38Volume388,240 shsAverage Volume568,886 shsMarket Capitalization$53.68 millionP/E RatioN/ADividend YieldN/ABeta1.03 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTOO Previous Symbol CUSIPN/A CIK1492674 Webhttp://www.t2biosystems.com/ Phone781-761-4646Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.50 million Price / Sales5.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book4.42Profitability EPS (Most Recent Fiscal Year)($1.26) Net Income$-51,150,000.00 Net Margins-851.71% Return on Equity-1,263.80% Return on Assets-120.66%Miscellaneous Employees153 Outstanding Shares46,680,000Market Cap$53.68 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive TTOO News and Ratings via Email Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TTOO Rates by TradingView T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions What is T2 Biosystems' stock symbol? T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO." How were T2 Biosystems' earnings last quarter? T2 Biosystems Inc (NASDAQ:TTOO) issued its earnings results on Tuesday, July, 30th. The medical equipment provider reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.03. The medical equipment provider had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.95 million. T2 Biosystems had a negative return on equity of 1,263.80% and a negative net margin of 851.71%. The firm's revenue was down 53.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.32) earnings per share. View T2 Biosystems' Earnings History. When is T2 Biosystems' next earnings date? T2 Biosystems is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for T2 Biosystems. What guidance has T2 Biosystems issued on next quarter's earnings? T2 Biosystems issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$8.7-9.6 million, compared to the consensus revenue estimate of $$9.32 million. What price target have analysts set for TTOO? 7 equities research analysts have issued 1 year target prices for T2 Biosystems' shares. Their forecasts range from $0.40 to $10.00. On average, they anticipate T2 Biosystems' stock price to reach $5.63 in the next twelve months. This suggests a possible upside of 389.4% from the stock's current price. View Analyst Price Targets for T2 Biosystems. What is the consensus analysts' recommendation for T2 Biosystems? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for T2 Biosystems. What are Wall Street analysts saying about T2 Biosystems stock? Here are some recent quotes from research analysts about T2 Biosystems stock: 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (11/15/2019) 2. HC Wainwright analysts commented, "We do not currently have a price target on TTOO shares. Risks include, but are not limited to: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; (2) failure to secure regulatory approval for T2Lyme; and (3) potential dilution risk." (8/7/2019) 3. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $10 on shares of TTOO. T2 reported 1Q19 product revenue of $1.3MM (+25% y/y), beating our estimate and VisibleAlpha consensus estimates by $0.3MM. Total 1Q19 revenue beat FactSet consensus and the top-end of management’s 1Q19 revenue guide. T2 closed on 11 T2Dx contracts during the quarter, above guidance of 8-10. Management reiterated 2019 revenue guidance and provided 2Q product revenue expectations of +35% growth at the midpoint. We are positive on the momentum of T2’s start to the year, and we continue to think that 2H19 will be pivotal for consumable revenue acceleration and consequently the shares." (5/3/2019) Has T2 Biosystems been receiving favorable news coverage? News articles about TTOO stock have been trending somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. T2 Biosystems earned a coverage optimism score of -1.8 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for T2 Biosystems. Are investors shorting T2 Biosystems? T2 Biosystems saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,730,000 shares, an increase of 11.3% from the September 30th total of 4,250,000 shares. Based on an average trading volume of 1,303,400 shares, the days-to-cover ratio is presently 3.6 days. Approximately 13.3% of the shares of the stock are short sold. View T2 Biosystems' Current Options Chain. Who are some of T2 Biosystems' key competitors? Some companies that are related to T2 Biosystems include Restoration Robotics (HAIR), Soliton (SOLY), iCAD (ICAD), TELA Bio (TELA), Spectral Medical (EDTXF), Cytosorbents (CTSO), BRAINSWAY LTD/S (BWAY), Neuronetics (STIM), STRATA Skin Sciences (SSKN), Liquidia Technologies (LQDA), Motus GI (MOTS), Nephros (NEPH), Apollo Endosurgery (APEN), Pro-Dex (PDEX) and Sensus Healthcare (SRTS). What other stocks do shareholders of T2 Biosystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Verastem (VSTM), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP) and Heron Therapeutics (HRTX). Who are T2 Biosystems' key executives? T2 Biosystems' management team includes the folowing people: Mr. John P. McDonough, CEO, Pres & Director (Age 59)Prof. Michael J. Cima, Co-Founder & Director (Age 59)Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 40)Dr. Tyler E. Jacks, Co-Founder (Age 58)Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board Who are T2 Biosystems' major shareholders? T2 Biosystems' stock is owned by a number of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (0.75%), Millennium Management LLC (0.49%), Granahan Investment Management Inc. MA (0.47%), Focused Wealth Management Inc (0.09%), Virtu Financial LLC (0.07%) and Cable Hill Partners LLC (0.07%). Company insiders that own T2 Biosystems stock include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Institutional Ownership Trends for T2 Biosystems. Which major investors are selling T2 Biosystems stock? TTOO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Virtu Financial LLC. Company insiders that have sold T2 Biosystems company stock in the last year include Alec Barclay, John Mcdonough, Michael J Cima, Michael Terrence Gibbs and Thomas J Lowery. View Insider Buying and Selling for T2 Biosystems. Which major investors are buying T2 Biosystems stock? TTOO stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Granahan Investment Management Inc. MA, Creative Planning, Commonwealth Equity Services LLC, Ironwood Financial llc, Founders Capital Management, Focused Wealth Management Inc and Cable Hill Partners LLC. View Insider Buying and Selling for T2 Biosystems. How do I buy shares of T2 Biosystems? Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is T2 Biosystems' stock price today? One share of TTOO stock can currently be purchased for approximately $1.15. How big of a company is T2 Biosystems? T2 Biosystems has a market capitalization of $53.68 million and generates $10.50 million in revenue each year. The medical equipment provider earns $-51,150,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. T2 Biosystems employs 153 workers across the globe.View Additional Information About T2 Biosystems. What is T2 Biosystems' official website? The official website for T2 Biosystems is http://www.t2biosystems.com/. How can I contact T2 Biosystems? T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected] MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 335 (Vote Outperform)Underperform Votes: 276 (Vote Underperform)Total Votes: 611MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2019 by MarketBeat.com StaffFeatured Article: Neutral Rating